According to Mercer, healthcare cost development has been about 6 percent since 2005, and while the rate is lower than the double-digit increases in previous years, it is still growing at a faster rate than inflation or workers’ wages. Blaine Bos, the writer of the study, said, It isn’t something to cheer about, especially since costs are getting passed on to employees. Related StoriesInnovative single-use torque instruments utilize difficult polycarbonate from BayerPreventing falls in care homes: an interview with Professor Pip LoganGreater evidence-based help necessary for depressed workers – New report from THE TASK FoundationThe survey also discovered that 47 percent of the companies are encouraging enrollment in wellness programs with lower premiums and higher deductibles, and that 19 percent intend to offer consumer-directed health plans with employee-controlled spending accounts.The lower incidence of serious adverse events in the romiplostim group as compared with the standard-of-treatment group indicates that romiplostim is normally a generally safe treatment option for sufferers, relative to additional therapies for immune thrombocytopenia. Bone marrow reticulin offers been detected in a small amount of sufferers treated with thrombopoietin mimetics26,27 and was observed in one individual in the romiplostim group during the 6-month post-treatment basic safety monitoring period. There have been no significant between-group differences, after adjustment for length of study-drug exposure, in the rates of reticulin fibrosis, thrombosis, or hematologic cancer during the treatment period.